Comparison Overview

Arch Pharmalabs, Ltd.

VS

Alkem Laboratories Ltd.

Arch Pharmalabs, Ltd.

"H" Wing, 4th Floor, Tex Centre, Andheri (E), Mumbai, undefined, 400 072, IN
Last Update: 2025-03-05 (UTC)

Founded in 1999,Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres. Arch Pharmalabs works tirelessly to deliver value, innovation and effective supply chain solutions in the spirit of true partnership. Our large family of satisfied customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a Preferred Supplier or Strategic Partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 678
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Alkem Laboratories Ltd.

Lower Parel Alkem House Mumbai, 400013, IN
Last Update: 2025-03-14 (UTC)
Between 750 and 799

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

NAICS: 325
NAICS Definition:
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Arch Pharmalabs, Ltd.
100%
Compliance Rate
0/4 Standards Verified
Alkem Laboratories Ltd.
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Arch Pharmalabs, Ltd. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alkem Laboratories Ltd. in 2025.

Incident History — Arch Pharmalabs, Ltd. (X = Date, Y = Severity)

Arch Pharmalabs, Ltd. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Alkem Laboratories Ltd. (X = Date, Y = Severity)

Alkem Laboratories Ltd. cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
Incidents

No Incident

https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
Incidents

No Incident

FAQ

Alkem Laboratories Ltd. company demonstrates a stronger AI Cybersecurity Score compared to Arch Pharmalabs, Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Alkem Laboratories Ltd. company has disclosed a higher number of cyber incidents compared to Arch Pharmalabs, Ltd. company.

In the current year, Alkem Laboratories Ltd. company and Arch Pharmalabs, Ltd. company have not reported any cyber incidents.

Neither Alkem Laboratories Ltd. company nor Arch Pharmalabs, Ltd. company has reported experiencing a ransomware attack publicly.

Neither Alkem Laboratories Ltd. company nor Arch Pharmalabs, Ltd. company has reported experiencing a data breach publicly.

Neither Alkem Laboratories Ltd. company nor Arch Pharmalabs, Ltd. company has reported experiencing targeted cyberattacks publicly.

Neither Arch Pharmalabs, Ltd. company nor Alkem Laboratories Ltd. company has reported experiencing or disclosing vulnerabilities publicly.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Arch Pharmalabs, Ltd. company nor Alkem Laboratories Ltd. company has publicly disclosed detailed information about the number of their subsidiaries.

Arch Pharmalabs, Ltd. company employs more people globally than Alkem Laboratories Ltd. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds SOC 2 Type 1 certification.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds SOC 2 Type 2 certification.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds ISO 27001 certification.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds PCI DSS certification.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds HIPAA certification.

Neither Arch Pharmalabs, Ltd. nor Alkem Laboratories Ltd. holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X